Developed by Johnson & Johnson, guselkumab (GUS) is the first approved fully-human, dual-acting IL-23p19 subunit inhibitor that blocks IL-23 and binds to CD64, a receptor on cells that produce IL-23.

Ozanimod showed a rapid onset of action and efficacy as extended induction therapy in patients with ulcerative colitis nonresponsive to biologics.

For both induction and maintenance therapy, subcutaneous guselkumab significantly improves clinical outcomes in patients with ...

The risk for both self-reported and symptomatic flare in inflammatory bowel disease is associated with psychosocial factors, ...

They dance in kitchens and in meadows frothy with flowers. They dance at weddings. They dance while fireworks bloom in dark ...

FAECAL microbiota transplantation (FMT) shows promise in treating ulcerative colitis (UC), with specific gut microbial ...

Reported positive interim pharmacokinetic ("PK") and safety data in Phase 1 trial of SPY001 in November 2024 and strengthened the balance sheet with a $230 million ...

Announced rosnilimab, a PD-1 depleter and agonist, achieved positive results from Phase 2b rheumatoid arthritis (RA) trial and highest-ever reported CDAI LDA response over 6 monthsFull clinical and tr ...